

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM460250

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Douglas Pharmaceuticals Ltd		01/31/2018	Limited Liability Company: NEW ZEALAND
RECEIVING PARTY DATA			
Name:	Tasman Pharma, Inc.		
Street Address:	1035 Louis Drive		
City:	Warminster		
State/Country:	PENNSYLVANIA		
Postal Code:	18974		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	4538214	VERSACLOZ	
CORRESPONDENCE DATA			
Fax Number:	6098961469		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	215.299.2081		
Email:	ipdocket@foxrothschild.com, colszyk@foxrothschild.com		
Correspondent Name:	Christopher D. Olszyk, Jr.		
Address Line 1:	997 Lenox Drive, Bldg. 3		
Address Line 4:	Lawrenceville, NEW JERSEY 08648-2311		
NAME OF SUBMITTER:	Christopher D. Olszyk, Jr.		
SIGNATURE:	/CDO/		
DATE SIGNED:	01/31/2018		
Total Attachments: 2			
source=VERSACLOZ Assignment 1.31.18#page1.tif			
source=VERSACLOZ Assignment 1.31.18#page2.tif			

OP \$40.00 4538214

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT (the "Assignment") is made and entered into effective as of 31 January 2018 (the "Effective Date") by **Douglas Pharmaceuticals Ltd.**, a New Zealand Limited Company having an address of Central Park Drive, Lincoln, PO Box 45 027, Auckland 0651, New Zealand (the "**Assignor**") in favor of **Tasman Pharma, Inc.**, a Delaware Corporation, having an address of 1035 Louis Drive, Warminster Pennsylvania 18974 (the "**Assignee**").

RECITALS

WHEREAS, Assignor is the sole and exclusive owner of all right, title and interest in and to the trademark identified as VERSACLOZ, and subject of Registration No. **4538214**, currently registered with the United States Patent and Trademark Office on 27 May 2014 (the "**Trademark**") together with the goodwill of the business symbolized by the Trademark.

WHEREAS, Assignor desires to assign to Assignee, and Assignee desires to acquire from Assignor, all of Assignor's right, title and interest in and to the Trademark, together with any and all goodwill of the business symbolized therewith.

NOW THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, Assignor hereby agrees as follows:

1. Assignor hereby assigns and transfers to Assignee all of Assignor's right, title and interest in and to the Trademark, together with the goodwill of the business symbolized by the Trademark, and including but not limited to any and all rights to sell and transfer, any subsidiary rights that may exist in the Trademark, the right to sue and recover any and all damages and profits, and any and all other remedies, for past, present or future infringements or violations thereof, all in Assignee's sole name.

2. This Assignment shall inure to the benefit of Assignee and its successors and assigns and shall be binding upon Assignor and its successors and assigns.

3. This Assignment and all questions relating to its validity, interpretation, performance and enforcement shall be governed by and construed in accordance with the laws of the State of Delaware, United States.

4. This Assignment may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.


[Signature page follows]

IN WITNESS WHEREOF, the Assignor has executed this Trademark Assignment effective as of the Effective Date first above written.

ASSIGNOR:

DOUGLAS PHARMACEUTICALS LTD.

By


Name (Signature)

Jeff Douglas
Name (Print)

Managing Director
Title

31 January 2018
Date

ASSIGNEE:

TASMAN PHARMA INC.

By


Name (Signature)

Jeff Douglas
Name (Print)

Director
Title

31 January 2018
Date